By Sneha S K

June 6 (Reuters) - Medical device maker Dexcom ( DXCM )

said the use of its continuous glucose monitor, G7, led to

improved blood sugar control in patients with type 2 diabetes

not using insulin, compared with routine care, according to

study results.

The results were presented on Saturday at the American

Diabetes Association.

Here are more details from the study:

* The 26-week study tested 283 non-insulin using diabetic

patients, of whom half were put on Dexcom's ( DXCM ) G7 and half used

self-monitoring of blood glucose. Most participants were on

common diabetes medication such as metformin, GLP-1s and SGLT2s.

* Participants using the Dexcom G7 saw an average 1.6%

reduction in their blood sugar levels at 26 weeks, a 0.9%

greater reduction than those who used self-monitoring.

* "Our hope is that this will substantially influence (the

standard of care) and it'll improve access for all people with

type 2, including those not on insulin to CGMs," Tamara Oser,

professor, at the University of Colorado Anschutz, and the

study's principal investigator, told Reuters.

* Continuous glucose monitors are wearable devices that

track blood sugar without finger pricks. Rising awareness,

broader insurance coverage and ease of use are boosting adoption

of devices like Dexcom's ( DXCM ) G7.

* The study found that using Dexcom G7 further lowered blood

sugar levels when combined with common diabetes medications.

* Among participants using GLP-1 drugs, those using the

Dexcom G7 saw a 1.4% drop in blood sugar levels, compared with a

0.2% reduction in the control group.

* "...it proves without a doubt that there's significant

benefit here for these users. I think both the clinical

community as well as the health care system and payers, they

will, with this type of result, recognize both the health

benefits, as well as the economic benefit," Dexcom ( DXCM ) CEO Jake

Leach told Reuters.

* These results "will help establish a new standard of

care in the U.S. and around the world," he said in a statement.

* A six-month extension phase of the study is currently

being conducted, which will provide data for up to 12 months.